8.49MMarket Cap-239P/E (TTM)
0.390High0.352Low416.04KVolume0.370Open0.335Pre Close156.95KTurnover2.26%Turnover RatioLossP/E (Static)21.89MShares5.01052wk High2.62P/B7.14MFloat Cap0.31552wk Low--Dividend TTM18.39MShs Float30.000Historical High--Div YieldTTM11.34%Amplitude0.315Historical Low0.377Avg Price1Lot Size
Mainz Biomed Stock Forum
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed presented findings from their largest cohort study at the ASCO 2024 Annual Meeting. The study, involving 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the US, confirmed the high sensitivity and specificity of their multimodal screening test for colorectal cancer (CRC) and advanced adenomas (AA). The test integrates Fecal Immunochemical T...
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Mainz Biomed will present its largest colorectal cancer screening study to date at the ASCO 2024 Annual Meeting. The study, combining data from ColoFuture and eAArly DETECT studies, includes 690 subjects across 30 clinical sites. The novel screening test, which uses mRNA biomarkers, FIT tests, and an AI algorithm, showed a 92.3% sensitivity for c...
NEWS
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
Mainz Biomed unveiled groundbreaking eAArly DETECT study results at Digestive Disease Week (DDW) 2024, achieving a Poster of Distinction award. The study demonstrated 97% sensitivity for colorectal cancer (CRC) and 82% for advanced precancerous lesions, with 100% detection in high-grade dysplasia patients. Conducted across multiple US sites with 2...
NEWS
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
No comment yet